 |
|
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park
Clin Mol Hepatol. 2022;28(2):254-264. Published online 2021 Dec 28 DOI: https://doi.org/10.3350/cmh.2021.0314
|
|
Citations to this article as recorded by
 Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B
Pin‐Nan Cheng, I‐Cher Feng, Jyh‐Jou Chen, Hsing‐Tao Kuo, Pei‐Lun Lee, Ming‐Lung Yu, Yen‐Cheng Chiu, Hung‐Chih Chiu, Shih‐Chieh Chien, Pei‐Jer Chen, Chun‐Jen Liu
Alimentary Pharmacology & Therapeutics.2024; 59(2): 230. CrossRef Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B
Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F. Flaherty, Irina Botros, Hajime Mizutani, Akinobu Ishizaki, Hiroki Konishi, Jason Yuan, Masahisa Jinushi, Leslie J. Ng
Journal of Viral Hepatitis.2024; 31(4): 165. CrossRef Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis
Kexin Tong, Mingjing Chen, Danni Wang, Haifeng Dai, Jiayi Peng, Jia Zhang, Jiao Zhou, Yujiao Chang, Wenxiang Huang
European Journal of Clinical Pharmacology.2024; 80(3): 335. CrossRef Application of Tenofovir Alafenamide Fumarate in Patients with Chronic Hepatitis B
雪 刘
Advances in Clinical Medicine.2024; 14(02): 3550. CrossRef The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang
Heliyon.2024; 10(7): e28653. CrossRef Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment
Jiezuan Yang, Haifeng Lu, Baikun Chen, Lili Jiang, Hua Zhang, Ping Ye, Linfeng Jin, Lele Zhu
Journal of Immunology Research.2023; 2023: 1. CrossRef Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113. CrossRef Tenofovir Alafenamide for Multiple Drug-Resistant Chronic Hepatitis B: A 3-Year Clinical Trial
Jonggi Choi, Young-Suk Lim, Ji-Hoon Kim, Kwan Soo Byun, Byung Chul Yoo
Clinical Gastroenterology and Hepatology.2023; 21(12): 3185. CrossRef Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
Eui Gwon Hwang, Eun-Ae Jung, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Hepatology International.2023; 17(4): 860. CrossRef Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623. CrossRef Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
Beom Kyung Kim, Sang Hoon Ahn
Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma
Peng Wang, Xinhui Wang, Xiaoli Liu, Fengna Yan, Huiwen Yan, Dongdong Zhou, Lihua Yu, Xianbo Wang, Zhiyun Yang
BMC Cancer.2023;[Epub] CrossRef Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won-Mook Choi, Young-Suk Lim
Clinics in Liver Disease.2023; 27(4): 809. CrossRef Comparisons of Insulin Resistance- and Steatosis-Based Scores in Monitoring Metabolic Associated Fatty Liver Disease Treatment Response
Junzhao Ye, Yansong Lin, Congxian Shao, Yanhong Sun, Shiting Feng, Bihui Zhong
Annals of Nutrition and Metabolism.2023; 79(5): 448. CrossRef Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clinical and Molecular Hepatology.2023; 30(1): 49. CrossRef Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
Hung-Yao Lin, Tai-Chung Tseng
Clinical and Molecular Hepatology.2022; 28(2): 181. CrossRef Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B
Meng‐Lan Wang, En‐Qiang Chen
Alimentary Pharmacology & Therapeutics.2022; 56(6): 1090. CrossRef
|